Krystal Biotech SEC Filings

American Shared Hospital Services (AMS) – Form 4 filing dated 06/30/2025 reports that Executive Chairman, Director and 10%+ owner Raymond C. Stachowiak received an award of 110,000 Restricted Stock Units (RSUs) on 06/26/2025 (Transaction Code A, price $0).

• Vesting schedule: 30,000 RSUs vest on each of June 27 2025 and July 2 2025; 25,000 RSUs vest on each of October 1 2025 and January 1 2026.
• Post-grant direct ownership rises to 664,678 common shares.
• Indirect holdings remain 158,500 shares through RCS Investments Inc. and 760,559 shares through Stachowiak Equity Fund LLC.
• Total beneficial ownership after the grant: ≈1.58 million shares.

The grant is part of executive compensation rather than an open-market purchase; nevertheless, it increases insider exposure and could be interpreted as a sign of continued commitment. No derivative securities were involved and no cash was exchanged, limiting near-term cash impact but introducing future dilution when RSUs convert to common shares.

Krystal Biotech, Inc. (KRYS) filed a Form 4 disclosing an equity compensation grant to director Daniel Janney on 30 June 2025.

• Type of security: Non-qualified stock option (right to buy common shares).
• Quantity: 5,000 options.
• Exercise price: $137.46 per share.
• Vesting schedule: Awards vest in equal monthly installments over 12 months beginning on the grant date.
• Expiration: 30 June 2035 (10-year term).
• Post-transaction beneficial ownership: 5,000 derivative securities reported as directly held; no change in non-derivative share ownership was reported.

The filing represents a routine director compensation grant. The size—5,000 options—equates to a low single-digit percentage of average daily trading volume and an immaterial fraction of KRYS’s ~25 million shares outstanding, implying limited dilution or market impact. No open-market purchases or sales were reported.

Krystal Biotech, Inc. (KRYS) filed a Form 4 disclosing an insider equity award to director Christopher Mason.

• Type of security: Non-qualified stock option giving the right to purchase 5,000 shares of common stock.
• Exercise price: $137.46 per share.
• Grant date: 06/30/2025; expiration: 06/30/2035.
• Vesting schedule: Equal monthly tranches over one year (per the footnote).
• Ownership status after grant: 5,000 derivative securities held directly; no non-derivative share movement reported.
• The filing was signed by Krish Krishnan as attorney-in-fact for Mason.

No sales, purchases, or other changes in common-stock holdings were reported, and no Rule 10b5-1 plan was indicated.

Blackstone Mortgage Trust, Inc. (BXMT) – Form 4 insider filing

Director Gilda Perez-Alvarado reported the receipt of 5,828 restricted Class A common shares on 27 Jun 2025. The award represents the cash value of the director’s $115,000 annual retainer and meeting fees, converted at the stock’s $19.73 closing price on the grant date. Following this transaction, Perez-Alvarado’s total direct beneficial ownership increased to 19,907 shares, up from roughly 14,079 shares before the award.

The shares are restricted stock, not open-market purchases, and will vest in full at the 2026 annual meeting, conditional on the director’s continued service. The filing uses transaction code “A,” indicating an equity award rather than a discretionary buy or sell. No derivative securities were involved, and no other transactions were reported.

While the grant modestly aligns the director’s incentives with shareholders, the $115 k value and 5.8 k-share issuance are immaterial relative to BXMT’s total shares outstanding and therefore should not meaningfully affect valuation or near-term liquidity.

Krystal Biotech, Inc. (KRYS) – Form 4 insider filing dated 06/30/2025

Director Catherine Mazzacco received a new equity award consisting of 5,000 stock options with an exercise price of $137.46 per share. The grant:

• Was awarded on 30 June 2025.
• Vests in 12 equal monthly tranches over one year, fully vesting by June 2026.
• Expires on 30 June 2035.
• Is held directly by the reporting person.

No shares were sold or otherwise disposed of; the filing reflects only an option acquisition (Code “A”). Upon full vesting and exercise, the option would give Ms. Mazzacco the right to purchase 5,000 shares of common stock, modestly increasing potential dilution but more importantly aligning her long-term incentives with shareholder value creation.

The filing is routine for director compensation and does not disclose any cash transactions, changes in company fundamentals, or earnings information.